Non-pharmacologic Treatments of Narcolepsy

Narcolepsy ◽  
2008 ◽  
pp. 313-322
Author(s):  
Renee Monderer ◽  
Shelby Freedman Harris ◽  
Michael J. Thorpy
Keyword(s):  
Pharmacologic Treatments

Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments

2014 ◽  
Vol 21 (5) ◽  
pp. 580-590 ◽  
Author(s):  
Arun Kanmanthareddy ◽  
Martin Emert ◽  
Rhea Pimentel ◽  
Yeruva Reddy ◽  
Sudharani Bommana ◽  
...  
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Lone Atrial Fibrillation ◽  
Pharmacologic Treatments

Cancer and Cancer Treatment-Related Cognitive Impairment

2019 ◽  
pp. 60-83
Author(s):  
James C.  Root ◽  
Elizabeth Ryan ◽  
Tim A. Ahles
Keyword(s):  
Cancer Survivors ◽  
Cancer Treatment ◽  
Clinical Presentation ◽  
Functional Neuroimaging ◽  
Theoretical Models ◽  
Future Research ◽  
Cognitive Changes ◽  
Central Nervous System Cancer ◽  
Pharmacologic Treatments

As the population of cancer survivors has grown into the millions, there is increasing emphasis on understanding how late effects of treatment impact survivors’ ability return to work/school, ability to function and live independently, and overall quality of life. Cognitive changes are one of the most feared problems among cancer survivors. This chapter describes the growing literature examining cognitive changes associated with non-central nervous system cancer and cancer treatment. Typical elements of cancer treatment are discussed, followed by a description of clinical presentation, self-reported and objectively assessed cognitive findings, and results of structural and functional neuroimaging research. Genetic and other risk factors for cognitive decline following treatment are identified and discussed, together with biomarkers and animal models of treatment-related effects. This is followed by a discussion of behavioral and pharmacologic treatments. Finally, challenges and recommendations for future research are provided to help guide subsequent research and theoretical models.

scholarly journals 6th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of Familial Hypercholesterolaemia

2015 ◽  
Vol 9 (1) ◽  
pp. 73-77
Author(s):  
Athyros VG
Keyword(s):  
Familial Hypercholesterolaemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Automatic Device ◽  
Loss Of Function ◽  
Ldl Apheresis ◽  
Cvd Risk ◽  
Atherosclerosis Risk In Communities ◽  
Lipid Disorder ◽  
Pharmacologic Treatments

Familial hypercholesterolaemia (FH) is the most common inherited monogenic lipid disorder. It is caused by mutations of genes related to low density lipoprotein (LDL) receptors, apolipoprotein B or proprotein convertase subtilisin/kexin type 9 (PCSK9). Homozygous FH (HoFH; 1/400,000 births) is treated by LDL apheresis. Recently lomitapide has been used for the treatment of HoFH as a monotherapy or in addition to LDL apheresis. Heterozygous FH (HeFH), 1/250-1/200 births, is associated with an increased cardiovascular disease (CVD) risk. The main treatment for HeFH has been high doses of high intensity statins plus ezetimibe. However, this is not usually enough to attain LDL-C targets, especially in those with overt CVD or equivalents (LDL-C goal of<70 mg/dl). Data from the Atherosclerosis Risk in Communities study showed that loss of function mutations of PCSK9 were associated with a 28% lower LDL-C level and an 88% reduction in the risk of CVD in blacks, while in whites these numbers were 15% and 47%, respectively. This led to the development of technology to block PCSK9 with monoclonal human antibodies (e.g. evolocumab and alirocumab). These antibodies have been shown in phase II and III trials to be safe and to produce reductions in LDL-C levels by around 60% either as monotherapy or on top of optimal therapy with statins and ezetimibe. These antibodies are administered subcutaneously every 2 weeks with an automatic device. Anti-PCSK9 antibodies are expected to be licensed soon (? in 2015) and are considered by many as “the statins of the 21st century”.

PHARMACOLOGIC TREATMENTS FOR DRUG AND ALCOHOL DEPENDENCE

1999 ◽  
Vol 22 (2) ◽  
pp. 401-423 ◽  
Author(s):  
Henry R. Kranzler ◽  
Hetal Amin ◽  
Vania Modesto-Lowe ◽  
Cheryl Oncken
Keyword(s):  
Alcohol Dependence ◽  
Pharmacologic Treatments ◽  
Drug And Alcohol

scholarly journals The Clinical Concept of Fibromyalgia as a Changing Paradigm in the Past 20 Years

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Mary-Ann Fitzcharles ◽  
Muhammad B. Yunus
Keyword(s):  
Gold Standard ◽  
Standard Treatment ◽  
Good Health ◽  
Pain Processing ◽  
Predictors Of Outcome ◽  
Rational Treatment ◽  
The Past ◽  
Active Patient ◽  
Pharmacologic Treatments ◽  
Clinical Concept

Fibromyalgia (FMS) is a valid clinical condition that affects 2%–4% of the population with a pivot symptom of widespread body pain. The cause and cure of FMS are as yet unknown. The concept of FMS has evolved over the past two decades to incorporate symptoms beyond pain as contributing to the global spectrum of suffering. FMS is now recognized to be grounded in the neurological domain with evidence of dysregulation of pain processing. Appreciation of the neurophysiologic mechanisms operative in FMS has contributed to rational treatment recommendations, although a “gold standard treatment” does not currently exist. Ideal treatments for FMS patients should be individualized with emphasis on active patient participation, good health practices, and multimodal intervention, incorporating nonpharmacologic and pharmacologic treatments. Predictors of outcome, which is favourable in over 50% of patients, are unknown, but those with better outcome do more physical activity and use fewer medications.

scholarly journals The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of ketamine and metabolites

2021 ◽  
Author(s):  
Philip Wolfson ◽  
Rob Cole ◽  
Kara Lynch ◽  
Cassandra Yun ◽  
Jason Wallach ◽  
...  
Keyword(s):  
Breast Milk ◽  
Postpartum Depression ◽  
Emotional Disorders ◽  
Pharmacokinetic Analysis ◽  
Emotional Difficulties ◽  
Lactating Women ◽  
Treatment Of Depression ◽  
Mother And Child ◽  
Pharmacologic Treatments ◽  
The Relationship

Abstract: There is no available data on the secretion and concentration of ketamine and its metabolites in breastmilk. There are statements in the literature made as to the safety of the use of ketamine in lactating women, though these are unsupported. This information is pertinent for the treatment of breastfeeding women who may have depression, PTSD, postpartum depression, and other emotional difficulties and would benefit from ketamine treatment. The objective of this study was to measure the presence and concentration of ketamine in breastmilk and three of its metabolites. We have provided a longitudinal pharmacokinetic analysis of the presence of ketamine and several of its major metabolites (norketamne, dehydronorketamine and hydronorketamine) in 4 women receiving 2 different intramuscular doses of ketamine—0.5mg/kg and 1.0mg/kg. Our results demonstrate the insignificance of ketamine’s presence In breast milk after a 12-hour period of suspension. Given ketamine’s proven record of effectiveness for the treatment of depression, and its intermittent use for this purpose, our data support the safety of its administration for the treatment of postpartum depression (PPD)and other emotional disorders during a woman’s chosen period to provide breast milk to her child without significant interruption or exposure. This provides the necessary data for the study of ketamine assisted psychotherapy as a potential treatment of postpartum emotional disorders without the loss of the relationship between mother and child which breast feeding so vitally provides. We review conventional pharmacologic treatments involved in the treatment of PPD.

scholarly journals Dental Anxiety Management by Full Spectrum CBD Formulations: Dual Dosing (AM/PM) Protocol in A Real-World Setting

2021 ◽  
Vol 3 (1) ◽  
pp. 034-041
Author(s):  
Cooper DL ◽  
Stephan R ◽  
Maygar CW
Keyword(s):  
Dental Health ◽  
Dental Anxiety ◽  
Data Sets ◽  
Paired Data ◽  
Full Spectrum ◽  
P Values ◽  
Anxiety Management ◽  
Group Data ◽  
Pharmacologic Treatments

Background: Dental Anxiety (DA) may produce a vicious cycle where dental problems are not adequately serviced. Chronic non-compliance with prescribed dental care and maintenance is associated ultimately with poor dental health. Current pharmacologic treatments such as benzodiazepines for DA are associated with poor efficacy and significant side effects.The anxiolytic effects of the most studied cannabinoid, cannabidiol (CBD) in the Dual Dosing (AM/PM) Full Spectrum Protocol are detailed here (DDFSP). Materials and methods: Our recently developed PhytoDental Solutions Dental Anxiety Scale (PDSDAS) composed of eight self-reported psychic, somatic and sleep indicators was utilized for scoring a subject’s DA level for three Time Groups (TG): the night before (T0); immediately after (T1); and 24 hours (T2) after a dental procedure or visit. Results: In this series of subjects completing at least one post-dosing time point, the Dual Dosing AM/PM Full Spectrum CBD (DDFSCBD) Protocol significantly reduced both psychic (43% to 67%) and somatic (51%) dental anxiety. Additionally, 87% of study patients reported substantially improved sleep the night before their dental visit. Kruskai-Wallis one-way ANOVA analysis of the three Time Group data sets yielded significant 1-tail statistical differences (p-values< 0.05) with p-values of 0.020 and 0.041 substantiating the role of the DDFSP to modify DA. Further, validation of the PDSDAS as a scoring measure developed for DA was extended by paired t-test comparisons to multiple smaller Paired Data sets across these Time Groups yielding 1-tail p-values of 0.010, 0.050 and 0.024 respectively. Conclusion: Determination of significance by both ANOVA and paired t-tests of PDSDAS scoring strongly suggest the Dual-Dosing (AM/PM) Full Spectrum Protocol is an effective Dental Anxiety anxiolytic.

Sign in / Sign up

Export Citation Format

Share Document